118 related articles for article (PubMed ID: 30550405)
1. Combination of ω-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study.
Ottes Vasconcelos R; Serini S; de Souza Votto AP; Santos Trindade G; Fanali C; Sgambato A; Calviello G
Melanoma Res; 2019 Jun; 29(3):270-280. PubMed ID: 30550405
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 Polyunsaturated Fatty Acids Enhance Cisplatin Efficacy in Gastric Cancer Cells by Inducing Apoptosis via ADORA1.
Sheng H; Chen X; Liu B; Li P; Cao W
Anticancer Agents Med Chem; 2016; 16(9):1085-92. PubMed ID: 27025656
[TBL] [Abstract][Full Text] [Related]
3. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
Sun X; Shi B; Zheng H; Min L; Yang J; Li X; Liao X; Huang W; Zhang M; Xu S; Zhu Z; Cui H; Liu X
Cell Death Dis; 2018 Feb; 9(3):260. PubMed ID: 29449532
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
Li W; Melton DW
Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
Wu QN; Liao YF; Lu YX; Wang Y; Lu JH; Zeng ZL; Huang QT; Sheng H; Yun JP; Xie D; Ju HQ; Xu RH
Cancer Lett; 2018 Jan; 412():243-255. PubMed ID: 29050982
[TBL] [Abstract][Full Text] [Related]
6. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
7. Fasting boosts sensitivity of human skin melanoma to cisplatin-induced cell death.
Antunes F; Corazzari M; Pereira G; Fimia GM; Piacentini M; Smaili S
Biochem Biophys Res Commun; 2017 Mar; 485(1):16-22. PubMed ID: 27693581
[TBL] [Abstract][Full Text] [Related]
8. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications.
Chu W; Pak BJ; Bani MR; Kapoor M; Lu SJ; Tamir A; Kerbel RS; Ben-David Y
Oncogene; 2000 Jan; 19(3):395-402. PubMed ID: 10656687
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line.
Zhao R; Rabo YB; Egyházi S; Andersson A; Edgren MR; Linder S; Hansson J
Anticancer Drugs; 1995 Oct; 6(5):657-68. PubMed ID: 8845476
[TBL] [Abstract][Full Text] [Related]
10. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
11. Polyunsaturated fatty acids inhibit melanoma cell growth in vitro.
Zajdel A; Wilczok A; Chodurek E; Gruchlik A; Dzierzewicz Z
Acta Pol Pharm; 2013; 70(2):365-9. PubMed ID: 23614295
[TBL] [Abstract][Full Text] [Related]
12. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J
J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965
[TBL] [Abstract][Full Text] [Related]
13. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
14. Macrovipecetin, a C-type lectin from Macrovipera lebetina venom, inhibits proliferation migration and invasion of SK-MEL-28 human melanoma cells and enhances their sensitivity to cisplatin.
Hammouda MB; Riahi-Chebbi I; Souid S; Othman H; Aloui Z; Srairi-Abid N; Karoui H; Gasmi A; Magnenat EM; Wells TNC; Clemetson KJ; Rodríguez-López JN; Essafi-Benkhadir K
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):600-614. PubMed ID: 29196192
[TBL] [Abstract][Full Text] [Related]
15. [Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells].
Zhang MC; Hu CP; Chen Q
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):408-12. PubMed ID: 17152483
[TBL] [Abstract][Full Text] [Related]
16. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
18. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U; Goey SH; Punt CJ; Proebstle TM; Salzmann R; Scheibenbogen C; Schadendorf D; Liénard D; Enk A; Dummer R; Hantich B; Geueke AM; Eggermont AM
J Clin Oncol; 1997 Jul; 15(7):2579-88. PubMed ID: 9215828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
